CClinicalTrials.gg
CompletedNCT01264471Updated Apr 13, 2015

Mechanisms of Mitochondrial Defects in Gulf War Syndrome

An observational study in Gulf War Syndrome and Mitochondrial Disease, sponsored by Medical Neurogenetics, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-13.

Sponsored by Medical Neurogenetics, LLC · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
26
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to investigate possible causes for Gulf War Syndrome. Gulf War Syndrome is associated with increased incidences of amyotrophic lateral sclerosis (Lou Gehrig's Disease), pain syndromes, muscle complaints that include fatigue and myalgias (muscle pain), as well as other neurological symptoms. Abnormalities in the part of the cell known as mitochondria have been delineated in Gulf War Syndrome. Mitochondria are the "power plants" of the body. Mitochondria take the food you eat and break the food down into a form of energy that the body can use. The investigators propose that Gulf War Syndrome is determined by a complex interaction of factors that interfere with mitochondrial function. This study will be the first investigation of mitochondrial function in Gulf War Syndrome. The investigators objective is to establish the cause for symptoms in affected veterans, develop testing that can more easily identify Gulf War Syndrome, and ultimately develop treatment protocols for Gulf War Syndrome.

02

Conditions studied

  • Gulf War Syndrome
  • Mitochondrial Disease

Keywords

  • Gulf War Syndrome
  • Gulf War Illness
  • Mitochondrial defects
  • Mitochondrial disorders
  • Persian Gulf Syndrome
03

In context

Mitochondrial Diseases

182 studies on the registry are indexed under Mitochondrial Diseases; 54 are open to participants now.

This study's enrollment of 26 is below the median of 60 across 72 observational studies indexed under Mitochondrial Diseases.

Browse Mitochondrial Diseases studies →

Lead sponsor

This is the only study on the registry with Medical Neurogenetics, LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Gulf War Veterans who have been diagnosed with Gulf War Syndrome

Inclusion criteria

  • Short-term memory loss or a severe inability to concentrate that affects work, school or other normal activities
  • Muscle Pain, myalgias
  • Pain without redness or swelling in a number of joints
  • Intense or changing patterns of headaches
  • Unrefreshing sleep
  • After any exertion, weariness that lasts for more than a day

Exclusion criteria

Exclusion Criteria:

  • Organ failure (e.g. emphysema, cirrhosis, cardiac failure, chronic renal failure)
  • Chronic infections (e.g. HIV/AIDS, hepatitis B or C)
  • Rheumatic and chronic inflammatory diseases (e.g. systemic lupus erythematosis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease, chronic pancreatitis.)
  • Major neurologic diseases (e.g. multiple sclerosis, neuromuscular diseases, epilepsy or other disease requiring ongoing medication that could cause fatigue, stroke, head injury with residual neurologic deficits)
  • Diseases requiring systemic treatment (e.g. organ or bone marrow transplantation; systemic chemotherapy; radiation of brain, thorax, abdomen, or pelvis)
  • Major endocrine diseases (e.g. hypopituitarism, adrenal insufficiency)
  • Myocardial infarction, heart failure
  • Morbid obesity (body mass index >40)
  • Permanent psychiatric exclusions: Lifetime diagnoses of bipolar affective disorders, schizophrenia or any subtype, delusional disorders of any subtype, dementias of any subtype, organic brain disorders, and alcohol or substance abuse within 2 years before onset of the fatiguing illness.
  • History of allergic reaction to lidocaine
  • History of keloid formation with skin incisions.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
26 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Gulf War Syndrome patients

    Gulf War veterans who have been diagnosed with Gulf War Syndrome.

    Procedure: Skin biopsy · Procedure: Blood Collection

Interventions

  • ProcedureSkin biopsy

    A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)

    Also known as: skin sample

  • ProcedureBlood Collection

    Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.

    Also known as: phlebotomy, blood draw

06

What researchers measure

Primary outcomes

  1. Characterize mitochondrial cellular energetics in Gulf War Syndrome patients

    After collecting a skin and blood sample, mitochondrial cellular energetics in Gulf War Syndrome patients will be characterized by: 1. high resolution respirometry of intact cells, 2. quantitative analysis of individual mitochondrial proteins, 3. analysis of intact OXPHOS enzyme complexes and supercomplexes, 4. in gel enzyme activity assessment of intact OXPHOS enzyme complexes and supercomplexes, 5. mitochondrial DNA (mtDNA) copy number quantitation to assess for defects in regulation mtDNA replication and 6. cellular coenzyme Q10 quantitation.

    Time frame: approximately 2 years; once all data has been collected from study participants

Secondary outcomes

  1. Mitochondrial DNA

    Assess the mitochondrial DNA (mtDNA) from each patient with Gulf War Syndrome for mtDNA mutations by whole genome sequencing of leukocyte and skin cell mtDNA.

    Time frame: approximately 2 years; once all data has been collected from study participants.

07

Study locations

1 site
  • Medical Neurogenetics, LLC
    Atlanta, Georgia 30342, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01264471
Lead sponsor
Medical Neurogenetics, LLC
Collaborators
United States Department of Defense
Responsible party
John M. Shoffner (Medical Director, Medical Neurogenetics, LLC) — Principal investigator
First posted
Dec 21, 2010
Start date
May 2009
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Apr 13, 2015

Study contacts

John M Shoffner, MD
principal investigator · Medical Neurogenetics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion